↓ Skip to main content

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

Overview of attention for article published in Alzheimer's Research & Therapy, October 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#49 of 607)
  • High Attention Score compared to outputs of the same age (92nd percentile)

Mentioned by

news
3 news outlets
twitter
5 tweeters

Citations

dimensions_citation
60 Dimensions

Readers on

mendeley
144 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
Published in
Alzheimer's Research & Therapy, October 2018
DOI 10.1186/s13195-018-0431-6
Pubmed ID
Authors

Philip Scheltens, Merja Hallikainen, Timo Grimmer, Thomas Duning, Alida A Gouw, Charlotte E Teunissen, Alle Meije Wink, Paul Maruff, John Harrison, Caroline M van Baal, Suzanne Bruins, Inge Lues, Niels D Prins

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 144 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 144 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 19 13%
Researcher 18 13%
Student > Master 17 12%
Student > Bachelor 15 10%
Other 9 6%
Other 22 15%
Unknown 44 31%
Readers by discipline Count As %
Medicine and Dentistry 19 13%
Neuroscience 17 12%
Psychology 10 7%
Agricultural and Biological Sciences 9 6%
Nursing and Health Professions 9 6%
Other 29 20%
Unknown 51 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 31. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2018.
All research outputs
#555,451
of 13,640,418 outputs
Outputs from Alzheimer's Research & Therapy
#49
of 607 outputs
Outputs of similar age
#19,940
of 262,560 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 1 outputs
Altmetric has tracked 13,640,418 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 607 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.3. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,560 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them